AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.41B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.51M
Average 0.76M
Returns on capital
AnaptysBio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.6%
avg -51.5%
ROIC
14.6%
avg -13.3%
ROA
-3.6%
avg -15.0%
Analysis
ROIC is currently the strongest return metric at 14.6% versus its period average of -13.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel R. Faga | President, Chief Executive Officer & Director | USD 517.8K | 46 | — | — |
Christopher Murphy | Chief Financial Officer | USD 517.31K | 42 | — | — |
John Kwon | Vice President of GI Clinical Development | — | — | — | — |
Monique Da Silva | Senior Vice President of Corporate Affairs | — | — | — | — |
Priya Raina | Senior Vice President of Clinical Operations | — | — | — | — |
Martin Dahl | Senior Vice President of Research | — | — | — | — |
Benjamin Stone | Chief Business Officer | — | 35 | — | — |
Cailin Sibley FACR | Senior Vice President of Translational Medicine | — | — | — | — |
Beth Mueller | Senior Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
42
$9.75M
Net Transaction Value
−$9.75M
Net selling
Most Active
Faga Daniel
13 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | RENTON HOLLINGS Direct | Sell | $249.4K$249,371.50 |
| Mar 30, 26Mar 30, 2026 | Schmid John P. Direct | Sell | $30K$29,962.23 |
| Mar 30, 26Mar 30, 2026 | Schmid John P. Direct | Sell | $426.8K$426,782.41 |
| Mar 30, 26Mar 30, 2026 | Schmid John P. Direct | Sell | $701.7K$701,706.79 |
| Mar 27, 26Mar 27, 2026 | Faga Daniel Direct | Sell | $202.5K$202,522.29 |
| Mar 27, 26Mar 27, 2026 | Faga Daniel Direct | Sell | $28.9K$28,872.63 |
| Mar 27, 26Mar 27, 2026 | Faga Daniel Direct | Sell | $148.8K$148,819.19 |
| Mar 27, 26Mar 27, 2026 | Faga Daniel Direct | Sell | $214.7K$214,651.06 |
| Mar 27, 26Mar 27, 2026 | Faga Daniel Direct | Sell | $29.2K$29,215.61 |
| Mar 27, 26Mar 27, 2026 | Faga Daniel Direct | Sell | $33.3K$33,344.52 |
1–10 of 42
Summary
Insiders reported 0 buys worth $0.00 and 42 sells worth $9.75M over the last 12 months. That adds up to net selling of $9.75M. Faga Daniel was the most active insider with 13 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +183.6% | +11.7% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | +50.9% (5yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +183.6% over three years. Forward estimates point to EBIT at +50.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does AnaptysBio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ANAB's management, answered from reported figures.
Who manages ANAB?
AnaptysBio, Inc. (ANAB) lists 9 active executives. The top listed executive is John Kwon, Vice President of GI Clinical Development.
Are ANAB insiders buying or selling?
Recent insider activity shows net selling of $8.27M.
Continue the stock analysis
Jump to another research area for this company.